⁍ The owners, led by Torsten Haferlach, have asked Goldman Sachs to find a buyer for the company.
⁍ MLL generates annual earnings before interest, tax, depreciation and amortisation of around 40 million euros.
⁍ Several private equity firms are studying the dossier and weighing the company’s revenue growth.
– The founders of Germany’s Munich Leukemia Laboratory (MLL) have decided it’s time to put the company up for sale, sources tell Reuters. Torsten Haferlach and Claudia Haferlach, along with other co-founders and managers, have asked Goldman Sachs to find a buyer for the firm, which focuses on leukemia diagnostics and research, the sources say. MLL’s annual earnings before interest, tax, depreciation, and amortisation are estimated at $47 million. The company has already sent out first information packages to prospective bidders, the sources say. Several private equity firms are studying the dossier and weighing the company’s revenue growth against factors such as the regulatory risk of potential price caps and the key-person-risk of MLL potentially facing difficulties should co-founders and managers—Torsten and Claudia Haferlach as well as Wolfgang Kern— decide to leave the company. MLL and Goldman Sachs declined to comment.
Source: https://www.reuters.com/article/mll-ma/munich-leukemia-laboratory-put-up-for-sale-sources-idUSL8N2HH2ZS